Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4084135
Max Phase: Preclinical
Molecular Formula: C20H27ClN2O5S
Molecular Weight: 442.97
Molecule Type: Small molecule
Associated Items:
ID: ALA4084135
Max Phase: Preclinical
Molecular Formula: C20H27ClN2O5S
Molecular Weight: 442.97
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C(C)(C)[C@H]2CCOC2)c1O
Standard InChI: InChI=1S/C20H27ClN2O5S/c1-12-5-4-6-15(12)22-19(25)23-16-8-7-14(21)18(17(16)24)29(26,27)20(2,3)13-9-10-28-11-13/h5,7-8,13,15,24H,4,6,9-11H2,1-3H3,(H2,22,23,25)/t13-,15+/m0/s1
Standard InChI Key: POGOIUASGHCZBK-DZGCQCFKSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 442.97 | Molecular Weight (Monoisotopic): 442.1329 | AlogP: 3.86 | #Rotatable Bonds: 5 |
Polar Surface Area: 104.73 | Molecular Species: ACID | HBA: 5 | HBD: 3 |
#RO5 Violations: 0 | HBA (Lipinski): 7 | HBD (Lipinski): 3 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 5.41 | CX Basic pKa: | CX LogP: 3.46 | CX LogD: 1.76 |
Aromatic Rings: 1 | Heavy Atoms: 29 | QED Weighted: 0.47 | Np Likeness Score: -0.55 |
1. Lu H, Yang T, Xu Z, Lin X, Ding Q, Zhang Y, Cai X, Dong K, Gong S, Zhang W, Patel M, Copley RCB, Xiang J, Guan X, Wren P, Ren F.. (2018) Discovery of Novel 1-Cyclopentenyl-3-phenylureas as Selective, Brain Penetrant, and Orally Bioavailable CXCR2 Antagonists., 61 (6): [PMID:29406702] [10.1021/acs.jmedchem.7b01854] |
Source(1):